Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer

Frontiers in Oncology

Volumn 3 AUG, Issue , 2013, Pages

  Tagawa, Scott T ^a   Akhtar, Naveed H ^a   Nikolopoulou, Anastasia ^a   Kaur, Gurveen ^a   Robinson, Brian ^a   Kahn, Renee ^a   Vallabhajosula, Shankar ^a   Goldsmith, Stanley J ^a   Nanus, David M ^a   Bander, Neil H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Monoclonal antibody; Myelotoxicity; Prostate cancer; Prostate specific membrane antigen; Radioimmunotherapy

Indexed keywords

MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY J591 177LU; MONOCLONAL ANTIBODY J591 90Y; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CYTOTOXICITY; DEATH; FEBRILE NEUTROPENIA; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; INFUSION RELATED REACTION; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; RADIOIMMUNOTHERAPY; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VERY ELDERLY;

EID: 84891116667     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00214     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63:11-30. doi:10.3322/caac.21166
2. Zelefsky MJ, Eastham JA, Sartor O. Cancer of the prostate. 9th ed. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Devita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. Philadelphia, USA: Lippincott Williams and Wilkins (2011). p. 1220-62.
3. Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res (2010) 16:3998-4004. doi:10.1158/1078-0432.CCR-10-0162
4. Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, et al. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by (90)Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann Oncol (2012) 23:415-20. doi:10.1093/annonc/mdr145
5. Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol (2013) 31:314-20. doi:10.1200/JCO.2012.42.4101
6. Divgi C. Editorial: what ails solid tumor radioimmunotherapy? Cancer Biother Radiopharm (2006) 21:81-4. doi:10.1089/cbr.2006.21.81
7. Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE, et al. Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol (1992) 10:45-54.
8. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med (1994) 35:1017-22.
9. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res (1996) 2:1289-97.
10. Meredith RF, Khazaeli MB, Macey DJ, Grizzle WE, Mayo M, Schlom J, et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res (1999) 5:3254-8.
11. Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm (1999) 14:99-111. doi:10.1089/cbr.1999.14.99
12. O'Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN, et al. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res (2001) 7:1561-8.
13. O'Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL, et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate (2002) 50:27-37. doi:10.1002/pros.10029
14. DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, et al. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin Cancer Res (2005) 11:7187-94. doi:10.1158/1078-0432.CCR-1004-0013
15. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res (2005) 11:5920-7.
16. Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin Cancer Res (2007) 13:5604-12. doi:10.1158/1078-0432.CCR-07-1071
17. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res (1994) 54:1807-11.
18. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 48:326-34. doi:10.1016/S0090-4295(96)00184-7
19. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 3:81-5.
20. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res (1987) 7(5B):927-35.
21. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res (1997) 57:3629-34.
22. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res (2000) 60:5237-43.
23. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 58:4055-60.
24. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol (2004) 22:2522-31. doi:10.1200/JCO.2004.09.154
25. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol (2005) 23:4591-601. doi:10.1200/JCO.2005.05.160
26. Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 116:1075-83. doi:10.1002/cncr.24795
27. Tagawa ST, Vallabahajosula S, Osborne J, Goldsmith SJ, Petrillo K, Tyrell L, et al. Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC) [abstract 4667]. J Clin Oncol (2010) 28(Suppl):S15.
28. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013). doi:10.1158/1078-0432.CCR-13-0231. [Epub ahead of print].
29. DeNardo GL, Siantar CL, DeNardo SJ. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm (2002) 17:107-18. doi:10.1089/10849780252824127
30. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm (2002) 17:445-64. doi:10.1089/108497802760363231
31. Aksentijevich I, Flinn I. Chemotherapy and bone marrow reserve: lessons learned from autologous stem cell transplantation. Cancer Biother Radiopharm (2002) 17:399-403. doi:10.1089/108497802760363196
32. Roboz GJ, Bennett JM, Coleman M, Ritchie EK, Furman RR, Rossi A, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res (2007) 31:1141-4. doi:10.1016/j.leukres.2006.11.011
33. Cheson BD. Some like it hot! J Clin Oncol (2001) 19:3908-11.
34. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood (2005) 105:4576-82. doi:10.1182/blood-2004-12-4690
35. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol (2007) 25:4285-92. doi:10.1200/JCO.2006.09.2882
36. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 21(7):1232-7. doi:10.1200/JCO.2003.06.100
37. Kaminski MS, Tuck M, Estes J. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced stage, follicular lymphoma: median 10 year follow-up results. Blood (2009) 114:3759.
38. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding N, Larsen SO, Philip P, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med (1985) 103:195-200. doi:10.7326/0003-4819-103-2-195
39. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol (2010) 28:4935-44. doi:10.1200/JCO.2010.29.1112
40. Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, et al. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. Cancer (2011) 117:5074-84. doi:10.1002/cncr.26182
41. Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol (2008) 26:1532-6. doi:10.1200/JCO.2007.13.4197
42. Ojha RP, Fischbach LA, Zhou Y, Felini MJ, Singh KP, Thertulien R. Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma. Cancer Epidemiol (2010) 34:274-8. doi:10.1016/j.canep.2010.04.003